Accelerate Diagnostics (AXDX) & Viveve Medical (VIVE) Head to Head Review
Accelerate Diagnostics (NASDAQ: AXDX) and Viveve Medical (NASDAQ:VIVE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.
This is a summary of recent recommendations for Accelerate Diagnostics and Viveve Medical, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Accelerate Diagnostics currently has a consensus price target of $33.00, suggesting a potential upside of 43.48%. Viveve Medical has a consensus price target of $10.50, suggesting a potential upside of 87.84%. Given Viveve Medical’s higher probable upside, analysts plainly believe Viveve Medical is more favorable than Accelerate Diagnostics.
Risk & Volatility
Accelerate Diagnostics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Viveve Medical has a beta of -0.34, suggesting that its share price is 134% less volatile than the S&P 500.
Insider & Institutional Ownership
44.4% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 65.6% of Viveve Medical shares are held by institutional investors. 51.4% of Accelerate Diagnostics shares are held by company insiders. Comparatively, 35.1% of Viveve Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Accelerate Diagnostics and Viveve Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Accelerate Diagnostics and Viveve Medical’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Accelerate Diagnostics||$1.29 million||985.93||-$61.92 million||($1.23)||-18.70|
|Viveve Medical||$10.42 million||10.41||-$25.39 million||($2.12)||-2.64|
Viveve Medical has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Viveve Medical, indicating that it is currently the more affordable of the two stocks.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.
Viveve Medical Company Profile
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician’s office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.